189 related articles for article (PubMed ID: 38249330)
1. Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.
Burcher KM; Bloomer CH; Gavrila E; Kalada JM; Chang MJ; Gebeyehu RR; Song AH; Khoury LM; Lycan TW; Kinney R; D'Agostino R; Bunch PM; Shukla K; Triozzi P; Furdui CM; Zhang W; Porosnicu M
Ther Adv Med Oncol; 2024; 16():17588359231217959. PubMed ID: 38249330
[TBL] [Abstract][Full Text] [Related]
2. Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature.
Bloomer CH; Gavrila E; Burcher KM; Kalada JM; Chang MJ; Gebeyehu RR; Asare E; Khoury LM; Kinney R; Frizzell B; Sullivan CA; Bunch PM; Porosnicu M
Ther Adv Med Oncol; 2023; 15():17588359231193722. PubMed ID: 37667781
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
4. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Taberna M; Oliva M; Mesía R
Front Oncol; 2019; 9():383. PubMed ID: 31165040
[TBL] [Abstract][Full Text] [Related]
9. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
11. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Machiels JP; Licitra LF; Haddad RI; Tahara M; Cohen EE
BMC Cancer; 2014 Jun; 14():473. PubMed ID: 24973959
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
18. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
19. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
20. Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
Liu J; Chen M; Gao X; Liu X; Zhao J; Pan R; Zhong W; Xu Y; Wang M
Thorac Cancer; 2023 Mar; 14(8):773-778. PubMed ID: 36725772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]